[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Montreal Heart Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":524},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,47,84,107,135,170,197,220,246,277,309,343,365,394,421,445,478,499],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100473856","phase-2-inhaled-milrinone-and-epoprostenol-for-the-prevention-of-difficult-cardiac-pulmonary-bypass-separation-100473856",false,"NCT05450328","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation","Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation: A Randomized, Double-blind, Controlled Trial","MILAN","Inclusion Criteria:\n\n\\- Only patients undergoing cardiac surgery with CPB and aged 18 years and older will be included in this study.\n\nExclusion Criteria:\n\n* The presence of congenital cardiomyopathy, which the correction is the primary objective of the proposed surgery. For example, a patient who requires surgery for atrial septal defect closure only would not be eligible for the study. On the other hand, a patient who undergoes this same surgery in addition to a valve replacement, for example, would be eligible to participate in the study.\n* Heart transplant or ventricular assist device surgery\n* Urgent surgery including hemodynamic instability requiring vasopressor agents upon arrival in the operating room\n* A contraindication to transesophageal ultrasound monitoring or the presence of an unstable cervical spine.\n* Presence of a contraindication related to Epoprostenol or Milrinone administration such as a documented left ventricular or right ventricular outflow tract obstruction, a severe unaddressed aortic stenosis, or a documented allergy to either of these two molecules.",true,"ALL","18 Years",{"count":21,"type":22},141,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","In cardiac surgery, the presence of pulmonary hypertension (PH) is a prognostic factor associated with increased mortality and morbidity. In this context, one of the main causes of PH is related to reperfusion ischemia during weaning from extracorporeal circulation (CPB). One of the consequences of PH is right ventricular dysfunction. During weaning from CPB, the development of a right ventricular dysfunction is associated with increased requirements for vasopressor and inotropic agents, duration of mechanical ventilation, prolonged intensive care and hospital stay, and increased mortality compared with patients with left ventricular (LV) dysfunction. The management of patients with PH with or without right ventricular (RV) dysfunction relies on several strategies such as the administration of intravenous and inhaled agents, or mechanical ventricular support. Among those agents, the administration of inotropes or pulmonary vasodilators such as epoprostenol, milrinone and nitric oxide are among the most widely used treatments recommended by the Canadian Cardiovascular Society. At the Montreal Heart Institute, inhaled epoprostenol and milrinone are routinely administered to patients with PH or LV dysfunction in the perioperative setting. Despite the frequent use of inhaled epoprostenol and milrinone, Health Canada has not yet approved the use of these molecules.\n\nThe primary objective of this multicenter, double-blind, randomized clinical trial is to evaluate the clinical efficacy of the combined administration of inhaled epoprostenol and milrinone in a cardiac surgery setting. This trial will compare the clinical outcome of 71 patients who will receive inhaled epoprostenol and milrinone before the start of bypass surgery to 71 patients who will receive a placebo before the start of the CPB. The primary clinical outcome is the proportion of patients with an \"unsuccessful\" CPB weaning defined by the use of an inotrope +\u002F- vasopressor agent or the use of mechanical circulatory support or a return to bypass grafting for hemodynamic reasons.\n\nThis clinical trial will evaluate the clinical efficacy of the combination of inhaled agents in a cardiac surgery setting. Therefore, if the results of this study are positive, the combination of inhaled epoprostenol and milrinone will optimize the management of patients with pulmonary hypertension with or without a right ventricular dysfunction.",[28,29],"Right Heart Failure","Right Ventricular Dysfunction",[31,29,32,33],"Cardiac Surgery","Cardiopulmonary Bypass","Inhaled Therapy","RECRUITING","2026-06-22",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":38},"2025-12-10",{"date":42,"type":22},"2028-12-01",{"name":44,"class":45},"Montreal Heart Institute","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":46},"100633257","phase-3-aspirin-in-subclinical-coronary-artery-disease-a-pilot-randomised-controlled-trial-100633257","NCT07524335","Aspirin in Subclinical Coronary Artery Disease: A Pilot Randomised Controlled Trial","ASCAD-P","Inclusion Criteria:\n\n1. Documented coronary atherosclerosis, as defined by one of the following criteria:\n\n   1. Coronary artery calcium (CAC) score \\> 0;\n   2. Cardiac CT angiography (CCTA) \u002F CoroScan: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery;\n   3. Coronary angiography: lesions \\\u003C70% in the right coronary (RCA), left anterior descending (LAD), and circumflex (Cx) arteries or their branches, and \\\u003C50% in the left main coronary artery; if performed, physiological coronary assessments (FFR, dPR, iFR, etc.) and intracoronary imaging (IVUS or OCT) must be negative for significant disease.\n2. Willing and able to provide informed consent and comply with study procedures\n\nExclusion Criteria:\n\n1. History of myocardial infarction (MI), coronary revascularization, stroke, transient ischemic attack (TIA), or peripheral arterial revascularization procedure;\n2. Current prescription or clear indication for aspirin, low-molecular-weight heparin (LMWH), direct oral anticoagulants, or any other antithrombotic medication;\n3. Clear contraindication to aspirin;\n4. History of significant bleeding within the past year;\n5. Severe illness with limited life expectancy (i.e., \\\u003C5 years);\n6. Any condition that, in the investigator's judgment, would make participation unsafe for the patient.","40 Years",{"count":56,"type":22},48,[58],"PHASE3","In patients with subclinical coronary artery disease, the ASCAD-P study aims to assess the feasibility of a larger phase 3 pragmatic randomized controlled trial comparing prescription versus no prescription of low-dose aspirin in routine clinical practice.",[61,62],"Coronary Artery Disease","Subclinical Atherosclerotic Cardiovascular Disease",[64,65,66,67,68,69,70,71,72,73,74],"Pilot Study","Feasability Study","Randomized","Clinical Trial","Prospective","Pragmatic Trial","Aspirin","Coronary artery disease","Bleeding","Major Adverse Cardiovascular Events","Antiplatelet","NOT_YET_RECRUITING","2026-05-07",{"date":78,"type":38},"2026-05-12",{"date":80,"type":22},"2026-05-01",{"date":82,"type":22},"2028-05-01",{"name":44,"class":45},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":18,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":46},"100459974","home-based-heat-therapy-for-type-2-diabetes-100459974","NCT05269589","Home-based Heat Therapy for Type 2 Diabetes","Impact of a Home-based Heat Therapy Intervention on Markers of Cardiometabolic Function in Adults With Type 2 Diabetes","Inclusion Criteria:\n\n* Age 45-75 years\n* Diagnosis of type 2 diabetes mellitus ≥1 year\n* Stable medication ≥12 weeks\n\nExclusion Criteria:\n\n* Class 3 obesity\n* Hypertension not controled by medication\n* Diagnosis of cardiac, renal and\u002For pulmonary disease\n* Diagnosis of severe neuropathy and\u002For retinopathy\n* Insulin therapy\n* Fasting plasma triglycerides \\>5.0 mmol\u002FL\n* Fasting total cholesterol \\>7 mmol\u002Fl","45 Years","75 Years",{"count":94,"type":22},44,[96],"NA","Insulin resistance and hyperglycemia predispose individuals with type 2 diabetes mellitus (T2DM) to endothelial dysfunction and a greater risk of cardiovascular diseases (CVD). Increased CVD risk in individuals with T2DM persists despite optimal pharmacological therapy, highlighting the need to identify complementary lifestyle interventions that improve cardiometabolic functions in this population. Evidence from animal models suggests that heat exposure improves metabolic functions. Notably, weekly heat exposure for 16 weeks blunts hyperinsulinemia and hyperglycemia induced by a high fat diet in mice. In parallel, studies in humans have shown that heat exposure improves vascular endothelial function. Based on such findings, it has been suggested that heat therapy may represent an effective lifestyle intervention to improve cardiometabolic functions. However, only 1 study has examined the impact of a heat therapy intervention on individuals with T2DM, demonstrating that 6 weeks of heat exposure reduces fasting plasma glucose and hemoglobin A1C. No study has considered potential vascular benefits of heat therapy in individuals with T2DM.\n\nThis project will investigate cardiometabolic responses to repeated heat exposure in men and women with T2DM. We will test the hypothesis that 12 weeks of heat therapy improves postprandial fatty acid handling, insulin sensitivity and endothelial function in individuals with T2DM.",[99,100],"Diabetes Mellitus, Type 2","Heat Exposure",{"date":78,"type":38},{"date":103,"type":38},"2022-02-18",{"date":105,"type":22},"2027-12",{"name":44,"class":45},{"id":108,"slug":109,"hasResults":11,"nctId":110,"briefTitle":111,"officialTitle":112,"acronym":113,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":18,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":124,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":133,"locationsCount":134},"100487953","phase-3-colchicine-and-non-enteric-coated-aspirin-in-the-cardiovascular-outcomes-trial-of-patients-with-type-2-diabetes-100487953","NCT05633810","COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes","COLchicine and Non-enteric Coated Aspirin in the Cardiovascular Outcomes Trial of Patients With Type 2 Diabetes (COLCOT-T2D)","COLCOT-T2D","Inclusion Criteria:\n\n1. Men and women aged 55 to 80 years\n2. Type 2 diabetes treated as per national guidelines\n3. No previous history of coronary artery disease-related clinical event\n4. And at least one of the following:\n\n   1. Duration of diabetes of 5 years or more,\n   2. HbA1c ≥ 8.0% or more in the last 2 years\n   3. Active cigarette smoking,\n   4. High hs-CRP (\\> 2.0 mg\u002FL),\n   5. High coronary calcium score (Agatston score \\>100),\n   6. High TG-levels (≥1.7 mmol\u002FL) despite lipid lowering therapy administered as per guidelines,\n   7. High LDL-C levels (≥3.5 mmol\u002FL) or high non-HDL-C levels (≥4.2 mmol\u002FL) despite lipid lowering therapy administered as per guidelines\n   8. High Apo-B (≥1.05 g\u002FL)\n   9. Reduced HDL-C (\\\u003C1.05 mmol\u002FL in men, \\\u003C1.3 mmol\u002FL in women),\n   10. Lp(a) \\>50 mg\u002FdL,\n   11. Peripheral artery disease with stenosis ≥50% or prior revascularization,\n   12. Cerebrovascular disease with stenosis ≥50% or prior revascularization,\n   13. Diabetic retinopathy or diabetic neuropathy,\n   14. Mild or moderate proteinuria (dipstick analysis) or micro-albuminuria\n5. Women of childbearing potential must have a negative urine pregnancy test at screening\u002Frandomization visit 1 and must agree to use an effective method of birth control throughout the study. Acceptable means of birth control include: oral contraceptives, implantable contraceptives, injectable contraceptives, transdermal contraceptives, intrauterine devices, male or female condoms with spermicide, abstinence, or a sterile sexual partner.\n\n   Women are considered not of childbearing potential if they either:\n   1. Have had a hysterectomy or tubal ligation prior to baseline visit or\n   2. Are postmenopausal defined as no menses for 12 months or a FSH level (if available) in the menopausal range.\n6. Patients with the capacity to provide informed consent.\n\nExclusion Criteria:\n\n1. Any prior history of myocardial infarction, angina, coronary revascularization, coronary stenosis \\>30%, stroke, transient ischemic attack, or known heart failure\n2. Known chronic renal insufficiency defined as an estimated glomerular filtration rate (eGFR), using the MDRD equation, of \\\u003C 35 mL\u002Fmin\u002F1.73m2\n3. History of cancer or lymphoproliferative disease within the last 3 years other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma and\u002For localized carcinoma in situ of the cervix and\u002For low-grade prostate cancer\n4. Inflammatory bowel disease (Crohn's disease or ulcerative colitis) or chronic diarrhea\n5. Peptic ulcer diagnosed within the last 24 months or previous gastro-intestinal bleeding, except for mild hemorrhoidal bleeding more than 5 years ago which is permitted (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n6. Pre-existent progressive neuromuscular disease or known CPK level \\> 3 times the upper limit of normal as measured within the past 30 days and determined to be non-transient through repeat testing\n7. Any of the following known parameters as measured within the past 90 days, and determined to be non-transient through repeat testing:\n\n   1. hemoglobin \\\u003C 100 g\u002FL\n   2. 2\\. white blood cell count \\\u003C 3.0 X 10⁹\u002FL\n   3. platelet count \\\u003C110 X 10⁹\u002FL\n   4. ALT \\> 3 times the upper limit of normal (ULN)\n   5. total bilirubin \\> 2 times ULN (unless due to Gilbert syndrome, which is allowed)\n8. History of cirrhosis, chronic active hepatitis or severe hepatic disease\n9. Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study or for 6 months after the last dose of study medication\n10. History of clinically significant drug or alcohol abuse in the last year\n11. Patient is currently using or plans to begin chronic systemic steroid therapy (oral or intravenous) during the study (topical or inhaled steroids are allowed, as well as replacement corticosteroids for adrenal insufficiency)\n12. Current chronic treatment with aspirin or another antiplatelet agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n13. Chronic treatment with an anticoagulant agent (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n14. Current use of colchicine for other indications (mainly chronic indications consisting of Familial Mediterranean Fever or gout); there is no wash-out period required for patients who have been treated with colchicine and stopped treatment prior to enrolment\n15. History of an allergic reaction or significant sensitivity to colchicine\n16. History of an allergic reaction or significant sensitivity to aspirin (patients meeting this exclusion criterion will not be randomized to receive aspirin or placebo but can be randomized to receive colchicine or placebo)\n17. Chronic treatment with an anti-inflammatory agent (for example, anti-TNF-alpha or nonsteroidal anti-inflammatory drug (NSAID))\n18. Use of an investigational chemical agent less than 30 days or 5 half-lives prior to the screening visit (whichever is longer)\n19. Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study.","55 Years","80 Years",{"count":118,"type":22},10000,[58],"To evaluate the efficacy and safety of colchicine and non-enteric coated aspirin, combined or alone, to improve cardiovascular outcomes in high-risk patients with type 2 diabetes.",[122,123],"Diabete Type 2","Cardiovascular Diseases",[125,126],"Diabetes (Type 2)","Heart Disease","2026-03-09",{"date":129,"type":38},"2026-03-10",{"date":131,"type":38},"2022-12-21",{"date":105,"type":22},{"name":44,"class":45},39,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":151,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":46},"100612716","phase-3-aspirin-free-strategy-with-ticagrelor-in-patients-with-a-myocardial-infarction-treated-medically-alone-100612716","NCT07257198","Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone","Evaluation of an asPirin-free Strategy With ticAgrelor in patieNTs witH a Myocardial Infarction treatEd Medically alONe (PANTHEON)","PANTHEON","Inclusion criteria:\n\n* Age ≥18 years;\n* Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;\n* Coronary angiogram performed;\n* Planned for medical management alone, without revascularization;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥12 months.\n\nExclusion criteria:\n\n* Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;\n* Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;\n* Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);\n* Confirmed or suspected spontaneous coronary artery dissection;\n* Concomitant indication for chronic oral anticoagulant;\n* Concomitant non-coronary indication for dual antiplatelet therapy;\n* Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;\n* Previous hospitalization for MI, PCI, or CABG within 12 months;\n* Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;\n* Unsuitability for either randomization treatment, based on the judgement of the treating physician",{"count":144,"type":22},2570,[58],"In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.",[148,149,150],"NSTEMI - Non-ST Segment Elevation MI","STEMI (ST Elevation MI)","Myocardial Infarction",[152,153,154,155,156,157,158,159,160,161,162],"Dual antiplatelet therapy","NSTEMI","medical treatment","STEMI","aspirin","ticagrelor","bleeding","ischemic events","randomized trial","pragmatic trial","randomized controlled trial","2026-03-08",{"date":129,"type":38},{"date":166,"type":38},"2026-03-03",{"date":168,"type":22},"2031-01-01",{"name":44,"class":45},{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":176,"eligibilityCriteria":177,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":178,"targetDuration":4,"studyType":23,"phases":180,"briefSummary":181,"conditions":182,"keywords":184,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100623032","dapt-strategy-in-hbr-patients-undergoing-complex-pci-following-acs-second-phase-beta-testing-of-a-patients-decision-aid-100623032","NCT07391358","DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid","Dual Antiplatelet Therapy Strategy in High Bleeding Risk Patients Undergoing Complex Percutaneous Coronary Intervention Following Acute Coronary Syndrome: Second-Phase Beta Testing of a Patients Decision Aid","BETA-DAPT","Inclusion Criteria (Patients)\n\n* Adults aged 18 years or older\n* Hospitalized on the coronary care unit ward at the Montreal Heart Institute (MHI)\n* Acute coronary syndrome (ACS) during the current episode of care, treated with PCI and placement of one or more coronary stents\n* High bleeding risk based on PRECISE-HBR score and high thrombotic risk, with both risks considered of comparable clinical importance by the treating medical team\n\nInclusion Criteria (Clinicians)\n\n\\- Clinicians working in the MHI coronary care unit (cardiologists, medical residents, nurse practitioners, or pharmacists) who use the patient decision aid with one or more study participants\n\nExclusion Criteria (Patients)\n\n* Receiving therapeutic anticoagulation\n* Planned cardiac surgery during the same episode of care\n* Prior history of coronary stent thrombosis\n* Antiphospholipid syndrome or known thrombophilia\n* Unable to participate in shared decision-making\n* Unable to understand spoken and written French or English\n* Concurrent participation in another study (followed within another research protocol)\n* Transferred from another center for reasons other than coronary angiography at MHI and expected to return to the referring center for ongoing care (i.e., \"fly-in\u002Ffly-out\" patients)",{"count":179,"type":22},26,[96],"Among patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI) and stent implantation, 17.5% are both at high bleeding risk (HBR) and have undergone complex PCI, which also places them at high thrombotic risk. In this population, several dual antiplatelet therapy (DAPT) strategies may be considered: (1) de-escalation of DAPT intensity after 1 to 3 months (switch from ticagrelor\u002Fprasugrel to clopidogrel), (2) shortening DAPT duration to 1 to 3 months followed by antiplatelet monotherapy, (3) 12-month clopidogrel-based DAPT, and (4) 12-month ticagrelor\u002Fprasugrel-based DAPT. Selecting the most appropriate DAPT strategy in this dual-risk context is complex, and clinical trial evidence is limited for this specific subgroup. In the absence of clear guideline recommendations to support decision-making for patients facing both elevated bleeding and thrombotic risks, structured shared decision-making support is needed.\n\nIn this context, within research project 2025-3499 conducted with pharmacy residents, we developed a patient decision aid (PDA) designed to support shared decision-making by helping patients understand their risks, available options, and potential consequences, so they can express their preferences regarding antiplatelet therapy. The PDA aims to facilitate shared decisions by improving patients' understanding of benefits and harms and aligning choices with patient values. A preliminary version of the tool has already undergone alpha testing with a small group of internal users (physicians, pharmacists, and patient partners). The next step is beta testing, that is, real-world testing with the target population and clinicians to evaluate usability and acceptability in routine practice.",[183],"Acute Coronary Syndrome",[185,186,187,188],"High bleeding risk","Complex percutaneous coronary intervention","Double antiplatelet therapy","Patient decision aid","2026-01-29",{"date":191,"type":38},"2026-02-05",{"date":193,"type":22},"2026-02-01",{"date":195,"type":22},"2026-12-31",{"name":44,"class":45},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":207,"conditions":208,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},"100545956","lipid-testing-after-myocardial-infarction-at-the-montreal-heart-institute-100545956","NCT06388668","Lipid Testing After Myocardial Infarction at the Montreal Heart Institute","Timing of Lipid Testing During Hospitalization for MI and Subsequent Management of Dyslipidemia An Observational Study to Reduce the Care Gaps in Dyslipidemia in Canada","Inclusion Criteria:\n\n* Adult patients ≥18 years old\n* Hospitalized at the Cardiac Care Unit for Myocardial Infarction (either NSTEMI or STEMI)\n* Lipid panel performed on day 0 of admission\n* Willing to provide informed consent\n\nExclusion Criteria:\n\n* None",{"count":205,"type":22},100,"OBSERVATIONAL","Because treatment decisions are usually based on a single measurement of the lipid panel at the time of an admission for an MI, the overarching objective of this project is to evaluate whether the measurement of LDL, non-HDL, and apoB values are reliable through all the duration of the hospitalization.\n\nIt will be a single-center, prospective, observational study will be conducted, including consecutive patients hospitalized for myocardial infarction at the Montreal Heart Institute.\n\nEvery patient at the Cardiac Care Unit will undergo non-fasting lipid panel testing at day 0 of their admission for Myocardial Infarction during the study period. Patients who consent to participate will have a 2nd non-fasting lipid panel drawn at day 2 of their admission.\n\nThereafter, the levels of the different lipid values from the panel will be compared between day 0, day 2, and 4-6 weeks after discharge.",[209,210,150],"Dyslipidemias","Lipid Testing","2025-12-02",{"date":213,"type":38},"2025-12-03",{"date":215,"type":38},"2024-06-01",{"date":217,"type":22},"2026-05",{"name":44,"class":45},2,{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":23,"phases":229,"briefSummary":231,"conditions":232,"keywords":236,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":46},"100493231","phase-1-assessing-pharmacokinetics-and-pharmacodynamics-of-daily-enteric-coated-aspirin-in-patients-with-stable-diabetes-ii-100493231","NCT05702463","Assessing Pharmacokinetics and Pharmacodynamics of Daily Enteric-coated Aspirin in Patients With StablE Diabetes II","APPEASEDII","Inclusion Criteria:\n\n1. Age ≥ 18 years;\n2. Participant must be naïve to ASA, defined as absence of chronic treatment with ASA within the previous 3 months, and of any ASA use within the previous 2 weeks;\n3. Type 2 diabetes, based on at least one of the following criteria: (5)\n\n   * Chronic treatment with oral antihyperglycemic agents or insulin therapy;\n   * Fasting Plasma Glucose (FPG) ≥ 126 mg\u002FdL (7.0 mmol\u002FL) (fasting is defined as no caloric intake for at least 8h);\n   * 2-h Plasma Glucose (2h-PG) ≥ 200 mg\u002FdL (11.1 mmol\u002FL) during the oral glucose tolerance test (OGTT);\n   * A1C ≥ 6.5% (48 mmol\u002Fml);\n4. Willing to attend all study visits of both the run-in and randomized phases of the trial.\n\nExclusion Criteria:\n\n1. Definitive indication for ASA, including any evidence of clinical atherosclerotic disease, previous or current;\n2. Known hypersensitivity to ASA;\n3. Patient requiring dialysis;\n4. Severe hepatic insufficiency or ALT \\> 3 x ULN;\n5. High-risk GI bleeding features, such as known H. pylori infection, past or present ulcer, history of bleeding from the GI tract;\n6. Bleeding diathesis;\n7. Platelet count or hemoglobin levels outside of the normal reference range;\n8. Planned major surgical procedure or dental procedure during the course of the study;\n9. Chronic inflammatory disease requiring regular anti-inflammatory treatment;\n10. Chronic treatment with an oral anticoagulant, an antiplatelet agent, NSAIDs or systemic steroids;\n11. Active cancer;\n12. History of hematological malignancy or myelodysplasia;\n13. Pregnant or lactating women;",{"count":228,"type":22},30,[230],"PHASE1","This phase 2 study will include patients suffering from type 2 diabetes mellitus and will first study their response to enteric coated aspirin at a dose of 80 mg per day for a 7-day period. Participants with an incomplete platelet inhibition after exposure to EC aspirin at doses of 80 mg once daily will be randomized to a random order of 3 different ASA regimens: EC ASA 162 mg once daily, EC ASA 81 mg twice daily and chewable ASA 40 mg twice daily. The aims are to determine the feasibility of a larger scale trial, and to determine the regimen associated with the lowest proportion of non-responders after randomization. Platelet function will be assessed at baseline and at day 7 of each arms of the study.",[233,234,70,99,235],"Platelet Aggregation","Type 2 Diabetes","Platelet Aggregation Inhibitors",[237,156,238,239],"diabetes","Acetylsalicylic acid","Pharmacodynamics",{"date":213,"type":38},{"date":242,"type":38},"2023-06-13",{"date":244,"type":22},"2027-07-01",{"name":44,"class":45},{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":252,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":256,"briefSummary":257,"conditions":258,"keywords":260,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":274,"leadSponsor":276,"locationsCount":46},"100434398","improving-renal-outcomes-following-coronary-angiography-andor-percutaneous-coronary-interventions-100434398","NCT04936607","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions","ImproviNg rEnal Outcomes Following Coronary angiograPhy and\u002For percuTaneoUs coroNary intErventions: a Pragmatic, Adaptive, Patient-oriented Randomized Controlled Trial","NEPTUNE","Inclusion Criteria:\n\n* Age ≥18 years;\n* Planned coronary angiogram and\u002For PCI;\n* Willingness to participate and to attend study visits;\n* Expected life expectancy ≥6 months.\n\nExclusion Criteria:\n\n* Cardiogenic or non-cardiogenic shock at the time of the procedure;\n* Emergent procedures (e.g. STEMI);\n* Iodine-based contrast media received within 2 days;\n* Presence of Intra-Aortic Balloon Pump (IABP);\n* Cardiac arrest within 24 hours;\n* Pre-procedural AKI defined using the modified KDIGO criteria within 7 days;\n* Renal replacement therapy;\n* Severe aortic or mitral disease;\n* LVEF \\\u003C30%.",{"count":255,"type":22},1158,[96],"The NEPTUNE triple-blind, active-placebo, adaptive, pragmatic, randomized trial aims to evaluate the effectiveness of a new intra-venous hydration strategy guided by left ventricular end-diastolic pressure (LVEDP), amount of contrast used, and baseline renal function, to prevent contrast-induced acute kidney injury (CI-AKI) and patient-oriented clinical endpoints in all-comer patients undergoing coronary angiogram and\u002For percutaneous coronary intervention (PCI).",[259],"Contrast-Induced Acute Kidney Injury",[261,262,263,264,265,266,267,268],"Randomized controlled trial","Pragmatic trial","Adaptive trial","Patient-oriented trial","Contrast-induced Nephropathy","Acute Kidney Injury","Coronary angiography","Percutaneous coronary intervention","2025-12-01",{"date":271,"type":38},"2025-12-08",{"date":273,"type":38},"2021-06-28",{"date":275,"type":22},"2027-07-31",{"name":44,"class":45},{"id":278,"slug":279,"hasResults":11,"nctId":280,"briefTitle":281,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":11,"sex":18,"minAge":284,"maxAge":4,"enrollmentInfo":285,"targetDuration":4,"studyType":23,"phases":287,"briefSummary":288,"conditions":289,"keywords":292,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":302,"lastUpdatePostDateStruct":303,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":46},"100437024","comparing-the-effects-of-combining-cognitive-and-physical-exercise-training-on-cognition-and-cerebral-blood-flow-regulation-in-men-and-women-with-chronic-heart-failure-100437024","NCT04970888","Comparing the Effects of Combining Cognitive and Physical Exercise Training on Cognition, and Cerebral Blood Flow Regulation in Men and Women With Chronic Heart Failure","ReCARDIO","Inclusion Criteria:\n\n* Age ≥ 50 years old\n* Stable chronic HF on maximally tolerated background treatment for at least 2 months (stable therapy with ACE-I, ARBs and MRA for at least 2 months), regardless of LVEF\n* with no limitation of physical activity in ordinary physical activity (i.e. NYHA class I), moderate symptoms (i.e. NYHA class II) or marked limitation in activity (i.e. NYHA class III)\n* Able to perform cognitive and physical training.\n\nExclusion Criteria:\n\n* Acute cardiovascular event 1 month prior to randomization, including emergency visit or hospitalization for decompensated HF, acute myocardial infarction, stroke, and transient ischemic attack\n* Planned cardiovascular intervention within 6 months (implantation of any cardiac device, cardiac revascularization, heart transplantation)\n* Severe exercise intolerance\n* Contraindications for exercise testing (e.g., uncorrected severe aortic or carotid stenosis, severe pulmonary hypertension, severe non-revascularizable coronary disease including left main coronary stenosis, significant myocardial ischemia or arrhythmia during low-intensity exercise, acute HF)\n* Severe respiratory disease\n* Non-cardiopulmonary limitation to exercise (e.g., arthritis, claudication or any peripheral neurological disease including other neurodegenerative diseases such as disabling Parkinson)\n* Uncontrolled diabetes or untreated thyroid dysfunction\n* Current or recent malignancy with life expectancy \\\u003C 1 year\n* Chronic hemodialysis or peritoneal dialysis\n* Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor.","50 Years",{"count":286,"type":22},216,[96],"The objective of this project is to assess the effects of combined physical exercise and cognitive training interventions on cognitive and brain health in patients with heart failure (HF). Also, the role of sex on the effects of the interventions will be assessed.",[290,291],"Chronic Heart Failure","Aging",[293,294,295,296,297,298,299,300,301],"cognition","physical exercise","cognitive training","brain functions","combined intervention","heart failure","biomarkers","cerebral vasoreactivity","fitness","2025-11-24",{"date":211,"type":38},{"date":305,"type":38},"2021-09-01",{"date":307,"type":22},"2026-12-01",{"name":44,"class":45},{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":318,"conditions":319,"keywords":328,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":342},"100609357","enhanced-valves-interventions-and-safe-ai-generated-end-results-100609357","NCT07213531","Enhanced Valves Interventions and Safe AI Generated End Results","ENVISAGE","Inclusion Criteria:\n\nPatients who have reached the age of legal majority under local laws.\n\n* For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an ECG- gating CT with:\n\n  1. five to ten image volumes at cardiac phases from 5% to 95% R-R\n  2. 0.625 mm slice thickness\n  3. 0.625 mm spacing between slices\n  4. 0.88 mm in-plane pixel spacing\n* For TMVI group: Patients who have had a TMVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For TTVI group: Patients who have had a TTVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For M-TEER: All patient who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Mitral valve, frame per second equal or higher than 40 frames per second, acceptable 3D reconstructions.\n* For T-TEER: All patient who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Tricuspid valve, frame per second equal or higher than 40 frames per second, acceptable transgastric image with acceptable 3D reconstructions.\n\nExclusion Criteria:\n\n* For TAVI group: Valve-in-valve procedures\n* For TMVI group: Valve-in-valve and valve-in-ring procedures\n* For TTVI: Valve-in-valve and valve-in-ring procedures\n* For M-TEER: G3 or older MitraClip, G1 Pascal\n* For T-TEER: G3 Triclip, G1 Pascal",{"count":317,"type":22},21000,"This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.",[320,321,322,323,324,325,326,327],"Heart Valve Disease","TAVI","M-TEER","TTVI","TMVI","T-TEER","Mitraclip","TriClip",[329,330,331,322,325,321,324,332,333],"Medical imaging","CT","Artificial intelligence","valvulopathy","predictive algorithms","2025-10-01",{"date":336,"type":38},"2025-10-09",{"date":338,"type":38},"2024-05-01",{"date":340,"type":22},"2029-05",{"name":44,"class":45},15,{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":23,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":46},"100565062","deployment-and-evaluation-of-artificial-intelligence-software-for-electrocardiogram-analysis-and-management-in-primary-care-100565062","NCT06637293","Deployment and Evaluation of Artificial Intelligence Software for Electrocardiogram Analysis and Management in Primary Care","DAISEA-ECG","Inclusion Criteria:\n\nFamily Physicians or Nurse Practitioners\n\nFamily physicians or nurse practitioners (NPs) practicing in one of the participating FMGs.\n\nFamily physicians who have given their free and informed consent. Patients\n\nAdult patients (18 years or older). Patients without follow-up in cardiology or internal medicine for cardiovascular issues (arrhythmia, heart failure, myocardial infarction, atherosclerotic coronary artery disease, valvular heart disease) or those who had a negative investigation in the past with no additional follow-up.\n\nECG\n\nAny 12-lead ECG performed with the MUSE GE 360 machine. ECG of adequate technical quality for interpretation (otherwise, it will be automatically rejected by the platform).\n\n\\-\n\nExclusion Criteria:\n\n* Family Physicians or Nurse Practitioners\n\nFamily physicians practicing exclusively in pediatrics (patients under 18 years old).\n\nFamily physicians unable to follow the project guidelines.",{"count":351,"type":22},2000,[96],"The DAISEA-ECG project aims to improve the diagnosis of heart diseases in primary care through the DeepECG platform, which combines ECG-AI and ECHONeXT algorithms. This study uses a stepped wedge design, where each Family Medicine Group acts as its own control. The FMGs will gradually transition from the control period (without AI recommendations) to the intervention period (with AI recommendations activated) in a randomized sequence.\n\nThe primary objective is to compare the sensitivity of family physicians in detecting cardiac pathologies, with and without the assistance of the DeepECG platform. Sensitivity is defined as the proportion of patients correctly referred to cardiology or for transthoracic echocardiography (TTE) among those who indeed required cardiovascular evaluation, as confirmed by an independent adjudication committee.",[355,356],"Primary Care Provider","Structural Heart Disease","2025-09-18",{"date":359,"type":38},"2025-09-19",{"date":361,"type":22},"2025-10-06",{"date":363,"type":22},"2027-03",{"name":44,"class":45},{"id":366,"slug":367,"hasResults":11,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":375,"briefSummary":376,"conditions":377,"keywords":380,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":386,"lastUpdatePostDateStruct":387,"startDateStruct":389,"completionDateStruct":391,"leadSponsor":393,"locationsCount":46},"100604069","prehabilitation-program-for-patients-awaiting-elective-heart-surgery-at-increased-risk-of-postoperative-complications-feasibility-and-potential-clinical-outcomes-100604069","NCT07144722","Prehabilitation Program for Patients Awaiting Elective Heart Surgery at Increased Risk of Postoperative Complications: Feasibility and Potential Clinical Outcomes","Preliminary Evaluation of a Prehabilitation Program for Adults Awaiting Elective Heart Surgery and at Increased Risk of Postoperative Complications","PRÉAD-CARDIAQU","Inclusion Criteria:\n\n* A high risk of perioperative and postoperative complications. This risk is determined based on the predictive thresholds for postoperative complications.\n* A waiting period of at least 8 weeks.\n* Access to a smartphone, tablet, or computer for videoconference visits.\n\nExclusion Criteria:\n\n* Unstable angina, malignant arrhythmias, active endocarditis\u002Fmyocarditis, myocardial infarction within the last 2 weeks, left main coronary artery disease ≥ 50% on coronary angiography, severe aortic stenosis, severe mitral insufficiency, and decompensated heart failure.\n* Any other acute condition affecting vital signs or causing significant symptoms.\n* Physical or cognitive impairment limiting the ability to participate in the program.",{"count":374,"type":22},45,[96],"The goal of this study is to learn if an exercise-based prehabilitation program can help people who are waiting for heart surgery and are at higher risk of complications recover better.\n\nThe main questions it aims to answer are:\n\nCan a home-based prehabilitation program prescribed by a physiotherapist be done safely and realistically before heart surgery?\n\nParticipants will:\n\nTake part in a personalized exercise program for a 8 to 16 weeks before surgery\n\nDo breathing muscle training at home\n\nMeet with a physiotherapist once a week, either in person or by video call\n\nBe assessed before and after the program\n\nResearchers will compare the postoperative results with those of patients who received usual care only.",[31,378,379],"Prehabilitation","Postoperative Complications",[381,382,383,384,385],"exercise-based prehabilitation","pulmonary postoperative complications","teleprehabilitation","elective surgery","cardiac procedures","2025-08-20",{"date":388,"type":38},"2025-08-27",{"date":390,"type":22},"2025-09-15",{"date":392,"type":22},"2026-06-15",{"name":44,"class":45},{"id":395,"slug":396,"hasResults":11,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":402,"targetDuration":403,"studyType":206,"phases":4,"briefSummary":404,"conditions":405,"keywords":407,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":46},"100601463","non-ischemic-cardiomyopathy-registry-biobank-and-imaging-data-repository-100601463","NCT07110818","Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository","Improving Risk Prediction in Non-ischemic Cardiomyopathy (NICM): An Individualized Multimodality Approach Registry, Biobank and Imaging Data Repository","CaNICM","Inclusion Criteria:\n\n1. LVEF \\\u003C50% and\u002For\n2. LVEF 50-55% with presence of clinically significant late gadolinium enhancement or LV dilatation and being carrier of a non ischemic cardiomyopathy causing gene (Pathogenic or likely pathogenic variant in a Clingen moderate or definite gene)\n\nExclusion Criteria:\n\n* A significant other cause of decreased LVEF such as:\n\n  1. Coronary artery stenosis (Significant lesion on proximal Left anterior descending or Left main, or ≥2 main branches with stenosis. Significant lesion is defined as \\>70% of any artery or \\>50% for the left main artery) or prior history of type 1 myocardial infarction\n  2. Significant congenital heart disease requiring intervention\n  3. Primary valvular disease including moderate to severe aortic stenosis and moderate to severe mitral stenosis, primary severe mitral regurgitation (secondary valvular disease such as mitral regurgitation\u002Ftricuspid regurgitation are not exclusion criteria)\n  4. Other distinct entities: Amyloid heart disease, Chagas, Takotsubo, sarcoidosis, hemochromatosis related cardiomyopathy, HIV related cardiomyopathy are excluded\n  5. Substances\u002Ftherapies induced cardiomyopathy only if they are deemed to be the sole explanation for the cardiomyopathy (at the discretion of the enrolling cardiologist)\n  6. Clear history of burned out hypertrophic cardiomyopathy\n  7. Already had a transplantation at time of first CMR\n  8. Refusal to provide informed consent\n\nAdditional remarks:\n\nPatients aged \\> 70 years of age at first contact with a cardiologist regarding the cardiomyopathy will be limited to maximum 10% of the total enrolled patients by center.\n\nPatients with risk factors (for example, chemotherapy, radiotherapy, alcohol…) for cardiomyopathy are not excluded unless they are deemed to completely account for the phenotype per the treating physician.\n\nThe inclusion is not restricted to adult patients and is planned to be extended to the pediatric population.\n\nAll included patients are recommended to have a CMR performed within 3 years of inclusion.",{"count":351,"type":22},"5 Years","The main goal of CaNICM is to create a central database that includes a biobank and an imaging data repository for patients with non-ischemic cardiomyopathy (NICM), as well as for at-risk family members. This includes people who carry rare genetic variants linked to NICM but do not show symptoms, and first-degree relatives.\n\nThe specific goals of this database and biobank are to:\n\nEnhance investigators' ability to predict the risk of heart rhythm disorders in patients with NICM.\n\nOptimize the timing and approach for screening family members who may carry the disease - determining who to test, when, and how.\n\nFind the best ways to treat family members early to prevent or slow the disease.\n\nFuture Phase - Phase 2 Goal:\n\n4\\. Prospectively evaluate how well this risk prediction model works in real-life clinical settings, and compare it to the current approach, which is often based on a single risk factor.",[406],"Non-ischemic Cardiomyopathy",[408,409,410,411,412],"genetic","echocardiography","cardiac magnetic resonance imaging","biomarker","risk prediction model","2025-08-07",{"date":415,"type":38},"2025-08-13",{"date":417,"type":38},"2024-04-02",{"date":419,"type":22},"2031-04-01",{"name":44,"class":45},{"id":422,"slug":423,"hasResults":11,"nctId":424,"briefTitle":425,"officialTitle":426,"acronym":427,"eligibilityCriteria":428,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":444},"100309075","clinical-monitoring-strategy-versus-electrophysiology-guided-algorithmic-approach-with-a-new-lbbb-after-tavi-100309075","NCT03303612","Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI","Comparison of a Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach in Patients With a New Left Bundle Branch Block After Transcatheter Aortic Valve Implantation (TAVI) a Bayesian Randomized Trial (COME-TAVI)","COME-TAVI","Inclusion Criteria:\n\n* Age ≥18 years\n* Informed consent to participate\n* Persistent new-onset LBBB after TAVI implantation (i.e. present at day 2)\n\nExclusion Criteria:\n\n* Prior pacemaker or implantable cardioverter-defibrillator\n* Pre-existing right bundle branch block (RBBB) or LBBB (i.e., prior to TAVI)\n* Class I or IIA indication for PPM implantation according to management guidelines",{"count":430,"type":22},250,[96],"The primary hypothesis of the proposed study is that an electrophysiology-based algorithmic approach is superior to standard clinical follow-up with 30-day monitoring in reducing the combined endpoint of syncope, hospitalization, and death in patients in patients with new of left bundle branch block following transcatheter aortic valve implantation (TAVI).",[434,435],"Left Bundle-Branch Block","Aortic Valve Stenosis","2025-05-05",{"date":438,"type":38},"2025-05-08",{"date":440,"type":38},"2017-10-15",{"date":442,"type":22},"2026-12",{"name":44,"class":45},10,{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":11,"sex":18,"minAge":453,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":477,"locationsCount":46},"100581872","vitamin-k-and-cognition-in-coronary-heart-disease-nutricog-100581872","NCT06855953","Vitamin K and Cognition in Coronary Heart Disease (NutriCog)","Vitamin K Supplementation to Improve Cognition of Patients With Coronary Heart Disease: a Randomized Controlled Pilot Study","Nutricog","Inclusion Criteria:\n\n* Men and women\n* Age 60 years and older\n* Medically documented stable Coronary Heart Disease (CHD)\n* Daily dietary intakes of phylloquinone \\\u003C150 mcg\n* Non-consumption of vitamin K supplements (i.e. K1 or K2, singly or in combination with other nutrients), or other cognitive aids\n* Good French or English understanding\n* Physical exercise not exceeding 2.5 hours\u002Fweek of moderate to vigorous aerobic activity\n* Capacity and willingness to sign informed consent\n\nExclusion Criteria:\n\n* Recent acute coronary syndrome (\\\u003C3 months) or recent coronary revascularization (bypass surgery or percutaneous coronary intervention, \\\u003C3 months)\n* Known left ventricular dysfunction (LVEF \\\u003C 40%) or chronic heart failure\n* Recent modification of medication (\\\u003C2 weeks)\n* Warfarin (Coumadin) use\n* Cognitive impairment (based on telephone version of the Mini-Mental State Examination test, score \\\u003C19\u002F23)\n* Diagnosis of depression or uncontrolled anxiety\n* Malabsorption disorder (advanced liver disease, Crohn's disease)\n* Patient with auditory or vision impairments not properly corrected by glasses or hearing aids\n* Unable to read the informed consent form or unable to understand the oral explanations provided by the assessor","60 Years",{"count":455,"type":22},40,[96],"The purpose of this pilot study is to obtain a preliminary assessment of the effect of VK supplementation on cognitive performance and vascular function in adults with stable Coronary Heart Disease (CHD)",[459],"Coronary Heart Disease",[461,462,463,464,465,466,467,468,469,470],"Coronary heart disease (CHD)","Cognition","Cerebral vasoreactivity","Nutrition","Heart disease","Cardiovascular disease","Vitamins","Micronutrients","Vitamin K","Vitamin K1","2025-02-25",{"date":473,"type":38},"2025-03-04",{"date":475,"type":22},"2025-03-17",{"date":363,"type":22},{"name":44,"class":45},{"id":479,"slug":480,"hasResults":11,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":491,"lastUpdatePostDateStruct":492,"startDateStruct":494,"completionDateStruct":496,"leadSponsor":498,"locationsCount":46},"100396369","patient-self-management-with-hemodynamic-monitoring-virtual-heart-failure-clinic-and-outcomes-100396369","NCT04441203","Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes","Patient SELF-management With HemodynamIc Monitoring: Virtual Heart Failure Clinic and Outcomes (the SELFIe-HF Trial): Program","SELFIe-HF","Inclusion Criteria:\n\n1. Male or female ≥ 18 years old.\n2. Symptomatic HF (NYHA III) with recent heart failure admission in the previous year (12 months). OR\n3. Patient with at least one ER visit or unplanned HF clinic requiring iv diuretics within 12 months will be eligible if they have in addition a N-terminal pro-BNP (NT-proBNP) level \\> 800pg\u002Fml at screening AND NYHA Class II on diuretics (furosemide ≥ 40mg qd), III or ambulatory IV.\n4. HF with reduced or preserved EF of at least 3 months duration.\n5. Minimum technological knowledge either with a smartphone or iPAD for use of the self-management application, including access to internet.\n6. Anatomical criteria\n\n   1. PA branch diameter between 7 mm - 15 mm\n   2. For BMI \\>35, distance from patient's back to target PA\\\u003C10cm\n\nExclusion Criteria:\n\n1. Recent cardiovascular event: Acute coronary syndrome (STEMI\u002FNSTEMI; a small rise in the troponin level would be expected in this population and is not a contraindication for enrolment); Percutaneous Coronary Intervention (PCI), new cardiac rhythm management (CRM) device (pacemaker, ICD and CRT), CRM system revision, lead extraction or cardiac or other major surgery or transient ischemic attack or stroke within 2 months (3 months of stabilization after CRT or cardiac surgery);\n2. Scheduled cardiac surgery;\n3. History of pulmonary embolism or recurrent deep vein thrombosis;\n4. Persistent NYHA Class IV and ACC\u002FAHA HF Stage D, patients implanted with a ventricular assist device (VAD), or patients listed for cardiac transplantation and likely to be transplanted within 12 months;\n5. Coexisting severe stenotic valve lesions, endocarditis, obstructive hypertrophic cardiomyopathy, acute myocarditis, tamponade, or large pericardial effusion;\n6. Clinically too unstable to be followed remotely; this includes but is not limited to:\n\n   1. Resting systolic blood pressure \\\u003C 80 or \\> 180 mmHg;\n   2. Resting heart rate \\> 100 bpm;\n   3. Stage IV or V chronic kidney disease (Estimated Glomerular Filtration Rate (eGFR) that remains \\\u003C 30 mL\u002Fmin\u002F1.73m2 by MDRD) or nonresponsive to diuretic therapy or on chronic renal dialysis;\n7. Severe pulmonary hypertension with systolic pulmonary artery pressure ≥80 mmHg;\n8. Pulmonary hypertension other than group II PH;\n9. Anemia requiring transfusions, iron infusions, or hemoglobin below 100;\n10. Coagulopathy or uninterruptible anticoagulation therapy or contraindication to antiplatelet\u002Fanticoagulant treatments anticipated in the protocol;\n11. Intolerance to aspirin or clopidogrel;\n12. Active infection requiring systemic antibiotics;\n13. Unwillingness to sign informed consent or to attend the outpatient clinic;\n14. Participation in another research trial with intervention;\n15. Discharge to a chronic care facility or residence in an outlying area;\n16. Pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception, such as the oral contraceptive pill, an intrauterine device or surgical sterilization. If necessary a negative urine or blood test will be performed before randomization\n17. Any condition that in the opinion of the investigator would jeopardize the evaluation for efficacy or safety or be associated with poor adherence to the protocol, including cognitive decline.\n18. Life expectancy \\\u003C1 year;",{"count":487,"type":22},150,[96],"To demonstrate that a virtual Heart Failure Clinic (HFC) based on patient self-management using Pulmonary Artery Pressure (PAP) monitoring is superior to usual care of HFC, leads to decreased: hospital admissions for heart failure (HF), emergency department consultation and\u002For unplanned intravenous heart failure therapy and cardiovascular death, compared to a regular HFC, has low device-related complications and is cost-effective, in New York Heart Association (NYHA) class III and II (requiring diuretics) patients.",[290],"2024-11-20",{"date":493,"type":38},"2024-11-22",{"date":495,"type":38},"2020-05-04",{"date":497,"type":22},"2025-12",{"name":44,"class":45},{"id":500,"slug":501,"hasResults":11,"nctId":502,"briefTitle":503,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":506,"targetDuration":4,"studyType":206,"phases":4,"briefSummary":508,"conditions":509,"keywords":512,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":518,"completionDateStruct":520,"leadSponsor":522,"locationsCount":523},"100423317","impact-of-fdg-petct-on-management-of-patients-with-native-valve-infective-endocarditis-100423317","NCT04792281","Impact of FDG-PET\u002FCT on Management of Patients with Native Valve Infective Endocarditis","PET-NAVIE","Inclusion Criteria:\n\n* 18 years of age or older, capable to provide informed consent;\n* Referred for a FDG-PET\u002FCT study\n* Classified as having Possible IE prior to FDG-PET\u002FCT imaging;\n* Patients must be able to tolerate the physical\u002Flogistical requirements of a PET\u002FCT scan.\n\nExclusion Criteria:\n\n* Subjects with prosthetic cardiac valve and\u002For CIED;\n* Pregnant or breastfeeding female;\n* Body mass index \\> 45 kg\u002Fm2.",{"count":507,"type":22},97,"The proposed study is a multicentric prospective observational cohort study of patients with suspected NVE. The study population includes those with Possible IE according to the modified Duke criteria and investigated at one of the 6 participating sites which include 2 cardiac centers, the MHI and the IUCPQ, as well as 4 tertiary care centers, the Jewish General Hospital , the McGill University Health Centre and the CHUS.",[510,511],"Infective Endocarditis","Native Valve Endocarditis",[513,514,515],"PET\u002FCT","FDG","Duke Criteria","2024-11-19",{"date":493,"type":38},{"date":519,"type":38},"2021-08-31",{"date":521,"type":22},"2025-12-31",{"name":44,"class":45},6,""]